Key facts
- This page summarizes Eldon C. Mayer III's Form 4 filing for Eiger BioPharmaceuticals, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 21 Mar 2023, 21:00.
Eldon C. Mayer III - 17 Mar 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.
- Reporting relationship
- Ex VP & Chief Commerc. Officer
- Issuer ticker
- N/A
- Reported as of
- 17 Mar 2023
- Net transaction value
- -$4,704
- SEC form
- 4
- Accepted by SEC
- 21 Mar 2023, 21:00:25 UTC
- Prior SEC filing
- 03 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eldon C. Mayer III
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Eldon C. Mayer III filed Form 4 for Eiger BioPharmaceuticals, Inc. on 21 Mar 2023.
Change
- Previous filing in this sequence was filed on 03 Mar 2023.
- Current net transaction value: -$4,704.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EIGR
transaction
Common Stock
Sale
- Transaction value
- $2,696
- Shares
- -2,520
- Change %
- -4.2%
- Price
- $1.07
- Shares after
- 57,948
- Date
- 17 Mar 2023
- Ownership
- Direct
- Footnotes
- F1
EIGR
transaction
Common Stock
Sale
- Transaction value
- $2,008
- Shares
- -1,875
- Change %
- -3.2%
- Price
- $1.07
- Shares after
- 56,073
- Date
- 17 Mar 2023
- Ownership
- Direct
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
These shares were sold by the reporting person in a pre-elected sell-to-cover transaction to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units ("RSUs") granted on March 11, 2022 for 16,000 shares.
Footnote F2
These shares were sold by the reporting person in a pre-elected sell-to-cover transaction to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 12, 2021 for 11,875 shares.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.07 to $1.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.